Drug Trial Radar · NCT05599516
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
Last checked: Nov 19, 2026Latest source record: Nov 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
16,000
Planned (sponsor's estimate)
Start
Nov 4, 2022
Primary completion
Oct 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- National Vaccine and Serum Institute, ChinaIndustry
- Sponsor type
- Industry
- Collaborators
- China National Biotec Group Company Limited; Lanzhou Institute of Biological Products Co., Ltd; Beijing Institute of Biological Products Co Ltd.
- First posted
- Oct 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial adopts a randomized, double-blind and placebo-controlled design. A total of 16000 participants are planned to be enrolled, of which, Cohort 1: 15000 participants vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1:1 with 1 dose of LIBP-Rec-Vaccine, BIBP-Rec-Vaccine or placebo intramuscularly to the deltoid muscle of upper arm. Cohort 2: 1000 participants vaccinated with ≥2 doses of mRNA COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1 with 1 dose of LIBP-Rec-Vaccine or BIBP-Rec-Vaccine intramuscularly to the deltoid muscle of upper arm.
Conditions
- COVID-19
- Coronavirus Infections
Interventions
LIBP-Rec-VaccineBiological
Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
BIBP-Rec-VaccineBiological
Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
placeboBiological
Intramuscular injection of placebo in the deltoid muscle of the upper arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Efficacy of LIBP-Rec-Vaccine/ BIBP-Rec-Vaccine against COVID-19 of immunization in healthy population aged 18 and above.Time frame: 14th day after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sheikh Khalifa Medical City
SEHA, Abu Dhab, United Arab Emirates · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.